Wilms Tumor

Wilms tumor clinical summary: does it cross the midline, presentation, differential, and workup notes for exams.

Maintained by Dr. Vivek Karn Review process: editorial policy

Medical Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment or direct patient care. Clinicians must exercise their independent judgment and verify all information, including drug dosages and treatment protocols, against current, officially approved guidelines and individual patient circumstances. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.

Wilms Tumor

Overview

Definition: Wilms tumor, also known as nephroblastoma, is the most common primary malignant renal tumor of childhood, originating from metanephric blastema. It typically presents as a large, solitary, unilateral abdominal mass.
Epidemiology:
- Incidence: Approximately 1 case per 10,000 live births.
- Age: Peak incidence between 2 and 5 years of age. It is rare in infants under 6 months and children over 8 years, though cases can occur at any age.
- Sex: Slightly higher incidence in females.
- Race: No significant racial predilection.
- Laterality: Over 90% are unilateral. Bilateral synchronous tumors occur in 5-10% of cases, often associated with genetic syndromes.
Classification:
- Histological:
  - Favorable Histology (FH): Accounts for approximately 90% of Wilms tumors. Characterized by triphasic components (blastemal, stromal, epithelial) or biphasic/monophasic variants without anaplasia. Prognosis is generally excellent.
  - Anaplastic Histology (AH): Accounts for 5-10% of Wilms tumors. Defined by the presence of diffuse nuclear anaplasia (enlarged, pleomorphic nuclei with prominent nucleoli and abnormal mitotic figures) within the tumor. This confers a worse prognosis and requires more intensive therapy. It can be focal or diffuse.
- Staging: Utilizes the Children's Oncology Group (COG) staging system (surgical-pathologic staging) or the International Society of Pediatric Oncology (SIOP) staging system (clinical-radiological staging, then surgical-pathologic).
  - COG Staging (Surgical-Pathologic):
    - Stage I: Tumor limited to the kidney and completely resected. Renal capsule intact. No residual tumor.
    - Stage II: Tumor extends beyond the kidney but is completely resected. Local extension (e.g., invasion of renal capsule, perirenal soft tissue, renal sinus vessels).
    - Stage III: Incomplete resection, regional lymph node involvement, peritoneal spillage, tumor implants on peritoneal surfaces, tumor thrombi in renal vein/IVC that extend to cut margin, piecemeal excision.
    - Stage IV: Hematogenous metastases (e.g., lung, liver, bone, brain) or distant lymph node involvement.
    - Stage V: Bilateral renal involvement at diagnosis. Each kidney is staged independently.
  - SIOP Staging (Clinical/Post-Nephrectomy): Similar categories but often based on pre-operative imaging for initial staging, followed by post-nephrectomy confirmation. SIOP focuses on pre-operative chemotherapy for most cases.

Pathophysiology

Mechanism: Wilms tumor arises from primitive metanephric blastema that fails to undergo normal differentiation. Genetic mutations play a crucial role.
- WT1 Gene: Located on chromosome 11p13, the WT1 gene is a tumor suppressor gene. Mutations are found in approximately 10-20% of sporadic Wilms tumors and are strongly associated with syndromes like WAGR (Wilms tumor, Aniridia, Genitourinary anomalies, intellectual disability/Retardation) and Denys-Drash syndrome. WT1 loss-of-function typically leads to early-onset Wilms tumor.
- WT2 Locus: Located on chromosome 11p15.5, this locus is implicated in conditions like Beckwith-Wiedemann syndrome (BWS) and hemihypertrophy, which increase Wilms tumor risk due to epigenetic dysregulation of imprinted genes (e.g., IGF2).
- Other Genes: Mutations in CTNNB1 (β-catenin), FZD2, SIX1, SIX2, MYCN, and TP53 (associated with diffuse anaplasia and Li-Fraumeni syndrome) are increasingly recognized. Loss of heterozygosity (LOH) at 1p and 16q are common genetic alterations associated with poorer prognosis, while gain of 1q is strongly associated with an unfavorable outcome.
Risk Factors:
- Genetic Syndromes:
  - WAGR Syndrome: Congenital aniridia (absence of iris), genitourinary anomalies (e.g., cryptorchidism, hypospadias, streak gonads), intellectual disability, and renal tumors (Wilms tumor risk up to 50%). Caused by deletion of 11p13, involving WT1 and PAX6.
  - Denys-Drash Syndrome: Characterized by pseudohermaphroditism, diffuse mesangial sclerosis (leading to early-onset renal failure), and Wilms tumor (risk ~90%). Caused by dominant-negative mutations in WT1.
  - Beckwith-Wiedemann Syndrome (BWS): Overgrowth syndrome (macrosomia, macroglossia, omphalocele, hemihypertrophy, visceromegaly). Increased risk of Wilms tumor (5-10%), hepatoblastoma, rhabdomyosarcoma. Associated with genetic abnormalities on 11p15.5.
  - Familial Wilms Tumor: Rare (1-2% of cases), linked to mutations in WT1 or FZD2.
  - Other less common associations: Simpson-Golabi-Behmel syndrome, Fraser syndrome, Perlman syndrome.
- Congenital Anomalies: Increased risk in children with isolated hemihypertrophy (localized overgrowth of one side of the body or limb), cryptorchidism, hypospadias, or nevi.
Protective Factors: None definitively identified. Early detection via screening for at-risk populations is key.

Clinical Presentation

Signs and Symptoms

Cardinal Features:
- Painless Abdominal Mass: The most common presentation (~80-90%). Typically noticed incidentally by a parent during bathing or dressing, or by a physician during a well-child check. The mass is usually firm, smooth, non-tender, and does not cross the midline (distinguishing it from neuroblastoma, which often crosses the midline and is irregular/nodular).
- Abdominal Pain: Present in about 30-40% of cases, usually due to rapid tumor growth, hemorrhage within the tumor, or tumor rupture.
- Abdominal Swelling: Noticeable distension.
Early Signs:
- Asymptomatic abdominal mass (most common).
- Mild, non-specific malaise.
Advanced Signs:
- Hematuria: Microscopic or macroscopic (15-25% of cases), often due to tumor invasion of the renal collecting system.
- Hypertension: Occurs in 25-60% of patients, likely due to renin production by the tumor, renal artery compression, or intrarenal arteriovenous shunting.
- Fever: Low-grade, non-specific (may indicate infection or tumor necrosis).
- Anorexia, Weight Loss, Vomiting: Less common, non-specific signs of advanced disease.
- Symptoms related to metastases:
  - Pulmonary: Cough, dyspnea, chest pain (if lung metastases).
  - Hepatic: Jaundice, right upper quadrant pain (if liver metastases).
  - Bone/Brain: Rarely seen at diagnosis but can occur.
Atypical Presentations:
- Sudden onset of acute abdomen with signs of peritonitis, often due to spontaneous tumor rupture and hemorrhage (a medical emergency).
- Varicocele due to obstruction of gonadal vein.
- Symptoms of vena caval obstruction (e.g., lower extremity edema, dilated abdominal wall veins, ascites) if tumor thrombus extends into the IVC.

Physical Examination

Inspection:
- Abdominal distension: May be visibly apparent, especially in thin children.
- Asymmetry: Unilateral abdominal bulge.
- Associated features: Aniridia, hemihypertrophy, genitourinary anomalies (hypospadias, cryptorchidism) suggestive of underlying syndromes.
Palpation:
- Abdominal Mass: Characteristically a large, firm, smooth, non-tender, solitary mass in the flank or upper abdomen. It rarely crosses the midline. Unlike neuroblastoma, it is generally confined to one side and less likely to be nodular.
- Important Precaution: Vigorous palpation should be avoided once a Wilms tumor is suspected, as it carries a theoretical risk of tumor capsule rupture, which would upstage the disease and worsen prognosis. Gentle palpation to characterize the mass is acceptable for initial assessment.
Special Tests: None specific for Wilms tumor, but a thorough systemic exam should be performed to look for signs of associated syndromes or metastasis. Auscultate for a bruit over the mass (rare). Check blood pressure for hypertension.

Diagnostic Approach

History Taking

Key Questions:
- Onset and Duration: When was the mass first noticed? How quickly has it grown?
- Associated Symptoms: Any abdominal pain, hematuria, fever, weight loss, changes in appetite or bowel habits?
- Family History: Any history of Wilms tumor or other childhood cancers? Any known genetic syndromes in the family?
- Personal Medical History: Any congenital anomalies (e.g., aniridia, hemihypertrophy, genitourinary anomalies)? History of growth abnormalities?
Red Flags:
- Rapidly enlarging abdominal mass.
- Presence of associated congenital anomalies or syndromic features (e.g., aniridia, hemihypertrophy).
- Unexplained hematuria or hypertension in a child.

Laboratory Tests

First-Line:
- Complete Blood Count (CBC) with differential: May show anemia (due to chronic blood loss or bone marrow suppression from advanced disease, though rare at presentation).
- Urinalysis (UA): To detect hematuria (microscopic or macroscopic).
- Renal Function Tests (RFTs): Serum creatinine, BUN, electrolytes to assess kidney function. Important for baseline assessment and to check for contralateral kidney function.
- Liver Function Tests (LFTs): Bilirubin, AST, ALT, alkaline phosphatase to assess for liver metastasis or dysfunction.
- Coagulation Profile (PT/INR, PTT): Essential before any surgical intervention.
- Urine Catecholamines (VMA, HVA): To rule out neuroblastoma, especially if the mass characteristics are atypical (e.g., crosses midline, irregular).
Confirmatory:
- Histopathological diagnosis: Definitive diagnosis relies on tumor biopsy or, more commonly in North America (COG approach), on the pathology of the nephrectomy specimen. Pre-operative biopsy is avoided by COG due to risk of spillage/upstaging, unless for bilateral tumors or specific cases where chemotherapy might preserve more renal parenchyma. SIOP strategy often involves pre-operative biopsy if diagnosis is uncertain, or pre-operative chemotherapy without biopsy for typical imaging findings.
Monitoring:
- Routine CBC, RFTs, LFTs during chemotherapy to monitor for toxicities.

Imaging

Recommended:
- Abdominal Ultrasound (US): Often the first imaging study performed for an abdominal mass. It can confirm a solid renal mass, differentiate it from other abdominal masses, and assess the contralateral kidney, renal vein, and inferior vena cava (IVC) for tumor extension. It is quick, non-invasive, and does not involve radiation.
- Computed Tomography (CT) of Abdomen and Pelvis with intravenous contrast: The gold standard for initial staging. It provides detailed information on tumor size, extent of local invasion, involvement of renal vessels, assessment of lymph nodes, and evaluation of the contralateral kidney. Crucially, it visualizes the IVC for tumor thrombus.
- CT of Chest with intravenous contrast: Essential for detecting lung metastases, which are the most common site of distant spread.
Advanced:
- Magnetic Resonance Imaging (MRI) of Abdomen: Useful as an alternative to CT, especially if contrast is contraindicated or for better delineation of tumor extension into the IVC or spinal canal. It can also be helpful for assessing bilateral tumors.
- Bone Scan/Brain MRI: Generally not routinely recommended at initial diagnosis unless specific symptoms or signs of bone/brain metastasis are present. Wilms tumor rarely metastasizes to bone or brain.

Management

Management of Wilms tumor is complex and requires a multidisciplinary team approach involving pediatric oncologists, surgeons, radiation oncologists, pathologists, and radiologists. There are two main approaches globally: the Children's Oncology Group (COG) approach (predominant in North America) and the International Society of Pediatric Oncology (SIOP) approach (predominant in Europe and other parts of the world).

Acute Management

Immediate:
- Stabilization: Assess patient's general condition (hydration, blood pressure).
- Avoid vigorous palpation: Reinforce the importance of avoiding excessive abdominal palpation once Wilms tumor is suspected, to prevent tumor rupture.
Stabilization:
- Blood Pressure Control: If hypertension is present, manage with antihypertensive medications (e.g., nifedipine, ACE inhibitors) to prevent complications.
- Fluid Balance: Ensure adequate hydration.
- Referral to Pediatric Oncology: Prompt referral to a specialized center is crucial.
Emergency:
- Tumor Rupture: If suspected (acute abdominal pain, guarding, signs of peritonitis), manage as a surgical emergency. This is rare at presentation but can occur.

Chronic Management

Management typically involves surgery, chemotherapy, and sometimes radiation therapy, depending on the stage and histology.

Pharmacological (Chemotherapy):
- Common Agents:
  - Vincristine (VCR): A vinca alkaloid, commonly used in all stages. Typical dose: 1.5 mg/m² IV (max 2 mg).
  - Actinomycin D (Act-D) / Dactinomycin: An antineoplastic antibiotic, also used in all stages. Typical dose: 45 mcg/kg IV (max 2 mg).
  - Doxorubicin (DOX): An anthracycline, used for higher stages (Stage III/IV) or unfavorable histology. Known cardiotoxicity. Typical dose: 60-75 mg/m² IV (cumulative lifetime max 300-450 mg/m²).
  - Cyclophosphamide (CYC): An alkylating agent, used for higher risk or refractory disease. Typical dose: variable, e.g., 600-1200 mg/m² IV.
  - Etoposide (VP-16): A topoisomerase II inhibitor, used in high-risk or recurrent settings. Typical dose: variable, e.g., 100 mg/m²/day for 3-5 days.
- Regimen Choice: Dependent on COG vs. SIOP approach, tumor stage, and histology.
  - Favorable Histology (FH):
    - Stage I/II FH: VCR + Act-D.
    - Stage III/IV FH: VCR + Act-D + DOX.
  - Anaplastic Histology (AH): More intensive regimens, often including VCR, Act-D, DOX, CYC, Etoposide.
Non-pharmacological:
- Surgical Resection:
  - Radical Nephrectomy: The cornerstone of treatment for unilateral Wilms tumor (in COG approach, usually upfront; in SIOP approach, post-chemotherapy). Involves removal of the kidney, surrounding fat, and regional lymph nodes. Lymph node sampling is critical for accurate staging.
  - Tumor Thrombus Management: If tumor extends into the renal vein or IVC, it requires careful surgical planning, potentially with cardiopulmonary bypass for suprahepatic/intracardiac extension.
  - Partial Nephrectomy: Considered only for very specific cases, such as bilateral tumors or a single kidney with a small, localized tumor, to preserve renal function.
- Radiation Therapy (RT):
  - Indications: Typically reserved for higher stages (Stage III/IV), unfavorable histology, tumor rupture, or residual disease.
  - Target Area: Abdominal or specific metastatic sites (e.g., lungs for lung metastases).
  - Dose: Varies based on indication and patient age (e.g., 10.8 Gy for Stage III FH, higher for AH or recurrent disease).
Monitoring:
- During Treatment: Regular blood counts, renal and liver function tests. Cardiac monitoring (echocardiograms) for patients receiving doxorubicin.
- Post-treatment Surveillance:
  - Clinical Exam: Regular physical exams, especially abdominal palpation.
  - Imaging:
    - Chest X-ray (CXR): Every 6-12 weeks for the first 2 years, then less frequently.
    - Abdominal Ultrasound (US): Every 3 months for the first 2 years, then every 4-6 months for the next 3 years. Some protocols use abdominal CT or MRI less frequently.
  - Follow-up duration: Intensive surveillance for the first 2-3 years (highest risk of relapse), then extended follow-up for 5-10 years or longer to monitor for late effects.

Treatment Algorithms

There are two primary, well-established approaches for Wilms tumor management:

COG (Children's Oncology Group) Approach (Predominant in North America):
1. Initial Diagnosis & Staging: History, physical exam, labs, abdominal/chest CT.
2. Primary Surgical Resection: For unilateral, presumed resectable tumors. Radical nephrectomy with lymph node sampling is performed first.
3. Pathological Staging & Histology Assessment: Based on the surgical specimen, the tumor is definitively staged (I-V) and classified as Favorable Histology (FH) or Anaplastic Histology (AH).
4. Adjuvant Chemotherapy: Based on stage and histology:
  - Stage I/II FH: 18-24 weeks of VCR + Act-D.
  - Stage III FH: 24 weeks of VCR + Act-D + DOX, and abdominal radiation therapy.
  - Stage IV FH: VCR + Act-D + DOX (duration depends on metastatic response), and usually radiation to metastatic sites (e.g., lungs).
  - Anaplastic Histology (AH) (regardless of stage): More intensive chemotherapy (e.g., VCR, Act-D, DOX, CYC, Etoposide) and radiation therapy (to abdomen and/or metastatic sites).
SIOP (International Society of Pediatric Oncology) Approach (Predominant in Europe):
1. Initial Diagnosis & Staging: History, physical exam, labs, abdominal/chest CT/MRI.
2. Pre-operative (Neoadjuvant) Chemotherapy: Most patients receive 4-6 weeks of VCR + Act-D (sometimes with DOX for larger/more advanced tumors) to shrink the tumor, reduce the risk of rupture, and allow for easier resection. A pre-operative biopsy is often performed if diagnosis is uncertain.
3. Surgical Resection: Radical nephrectomy (after pre-op chemo).
4. Pathological Staging & Histology Assessment: Tumor is staged based on pre-op imaging AND post-op pathology. Histology (FH/AH) is crucial.
5. Post-operative Chemotherapy: Tailored based on stage, histology, and response to pre-operative chemotherapy.
  - FH: Duration and agents vary based on stage, but generally VCR + Act-D +/- DOX.
  - AH: More intensive regimens.
6. Radiation Therapy: Indicated for higher stages, AH, or poor response to chemotherapy.
Refractory Cases (Relapsed Wilms Tumor):
- Management of relapsed Wilms tumor is complex and depends on initial treatment, site of relapse, and time to relapse.
- Often involves more intensive chemotherapy regimens (e.g., including high-dose cyclophosphamide, etoposide, carboplatin, ifosfamide) and targeted radiation.
- Surgery may be indicated for local relapse or to resect metastatic lesions.
- High-dose chemotherapy with autologous stem cell rescue may be considered for selected cases.
- Clinical trials for novel agents (e.g., immunotherapy, targeted therapies) are important options.

Complications

Common:
- Hypertension: Due to renin secretion or renal artery compression, requiring antihypertensive medication.
- Tumor Rupture: Can occur spontaneously or with excessive palpation, leading to hemorrhage, peritonitis, and disease upstaging.
- Treatment-related toxicities:
  - Myelosuppression: Common with chemotherapy, leading to neutropenia, anemia, thrombocytopenia (risk of infection, bleeding).
  - Nausea, Vomiting, Mucositis: Common side effects of chemotherapy.
  - Peripheral Neuropathy: From Vincristine (e.g., constipation, foot drop, jaw pain).
  - Cardiotoxicity: From Doxorubicin (e.g., acute arrhythmias, chronic cardiomyopathy). Requires careful monitoring (echocardiograms) and dose limitations.
  - Nephrotoxicity: From certain agents (e.g., ifosfamide, cisplatin, though less commonly used for Wilms).
Serious:
- Vena Cava/Right Atrial Thrombus: Can lead to significant hemodynamic compromise or pulmonary embolism. Requires specialized surgical expertise.
- Pulmonary Embolism: Rare but life-threatening, especially with IVC tumor thrombus.
- Hepatic Veno-Occlusive Disease: A rare but severe complication, particularly after high-dose chemotherapy or radiation to the liver.
- Secondary Malignancies: Increased risk of developing second primary cancers (e.g., acute myeloid leukemia, sarcomas, thyroid cancer) later in life due to chemotherapy and radiation exposure.
Long-term:
- Renal Impairment: Especially if partial nephrectomy was not possible, or if contralateral kidney is affected or damaged by radiation.
- Cardiovascular Complications: Chronic cardiomyopathy from doxorubicin.
- Growth and Developmental Issues: Can be affected by extensive treatment, especially if CNS involvement or brain radiation.
- Infertility: A concern for some patients, particularly with pelvic radiation or specific chemotherapy regimens.
- Scoliosis: Can occur with unilateral abdominal radiation.
- Chronic Fatigue, Pain, Neuropathy: Persistent issues in survivors.
- Psychosocial Impact: Significant for the child and family, requiring ongoing support.

Prognosis

Factors:
- Histology: The single most important prognostic factor. Favorable Histology (FH) has a significantly better prognosis than Anaplastic Histology (AH).
- Stage at Diagnosis: Lower stages (I/II) have excellent outcomes, while higher stages (III/IV) or bilateral disease (Stage V) carry a worse prognosis.
- Patient Age: Patients under 2 years or over 8 years at diagnosis may have a slightly worse prognosis, though histology and stage are more dominant.
- Genetic Aberrations: LOH at 1p and 16q, and gain of 1q are associated with poorer outcomes and typically lead to more intensive therapy.
- Response to Pre-operative Chemotherapy (SIOP approach): Good tumor shrinkage indicates favorable biology.
- Tumor Volume/Size: Larger tumors tend to be associated with higher stages.
Survival:
- Overall 5-year survival rates for Wilms tumor are excellent, exceeding 90% for favorable histology.
- Stage I/II FH: >95%
- Stage III/IV FH: 80-90%
- Anaplastic Histology: Significantly lower, ranging from 50-70% depending on stage and diffuse vs. focal anaplasia.
- Relapsed Disease: Survival is lower but still salvageable in many cases, depending on timing and site of relapse.
Quality of Life: Most long-term survivors achieve a good quality of life. However, they require lifelong surveillance for late effects of treatment (cardiac, renal, secondary malignancies, psychosocial issues).

Prevention

Primary: No known primary prevention strategies for sporadic Wilms tumor.
Secondary:
- Surveillance for At-Risk Populations: For children with genetic syndromes or congenital anomalies associated with an increased risk of Wilms tumor (e.g., WAGR, Denys-Drash, Beckwith-Wiedemann Syndrome, hemihypertrophy), regular abdominal ultrasound screening is recommended.
  - Protocol: Typically, abdominal ultrasound every 3 months until age 7-8 years (or 5 years in BWS), as per specific syndrome guidelines (e.g., COG guidelines for syndromic screening). This allows for early detection of tumors, often when they are smaller and at lower stages, leading to better outcomes.
Tertiary:
- Prevention of Complications: Comprehensive long-term follow-up and monitoring for late effects of treatment (e.g., cardiac surveillance for doxorubicin-exposed patients, renal function monitoring, scoliosis screening after radiation) is crucial to prevent or mitigate chronic sequelae.
- Education: Educating families and patients about potential late effects and the importance of adherence to follow-up schedules.

Special Populations

Pediatric: Wilms tumor is overwhelmingly a pediatric cancer; therefore, all information above is implicitly pediatric-focused. The approach to diagnosis and treatment must consider the unique physiological and developmental aspects of children.
- Infants (<1 year): Tumors in this age group can sometimes be congenital mesoblastic nephromas (benign), but Wilms tumor can occur. Diagnosis often requires biopsy.
- Adolescents/Young Adults: Rare, but can occur. Often presents at higher stage or with anaplastic features. May have different underlying molecular biology.
Geriatric: Wilms tumor is exceedingly rare in the geriatric population. When it occurs, it's often a misdiagnosis or a very rare adult variant. Management would be adapted based on general adult oncology principles and comorbidities.
Pregnancy: Not applicable, as Wilms tumor is a childhood cancer.
Comorbidities:
- Renal Insufficiency: If pre-existing renal dysfunction or single kidney, treatment modifications (e.g., nephron-sparing surgery, dose adjustments for renally excreted drugs) are necessary.
- Cardiac Conditions: Careful cardiac monitoring and lower cumulative doxorubicin doses in patients with pre-existing cardiac issues.
- Developmental Delays/Syndromes: Requires a multidisciplinary approach with consideration of neurodevelopmental and genetic counseling.

Clinical Pearls

Diagnostic:
- Rule of Thumb: Any persistent, firm, non-tender abdominal mass in a child should be presumed to be a Wilms tumor until proven otherwise.
- Imaging First: Prompt imaging (ultrasound, then CT chest/abdomen) is the priority. Do not biopsy if imaging is classic for Wilms tumor, especially in the COG approach, as it can upstage the disease.
- Beware the Midline: Wilms tumor rarely crosses the midline; neuroblastoma often does. Neuroblastoma is also typically irregular, firm, and nodular.
- Syndromic Search: Always look for associated syndromes (aniridia, hemihypertrophy, genitourinary anomalies) during the physical exam.
Treatment:
- Multidisciplinary Team: Management must involve a specialized pediatric oncology team (surgeons, oncologists, radiation oncologists).
- Staging is Key: Accurate surgical-pathologic staging is paramount for determining appropriate adjuvant therapy and prognosis. Comprehensive lymph node sampling is critical.
- COG vs. SIOP: Understand the differences in approach (upfront surgery vs. pre-op chemo) and follow the protocol of the treating institution.
- Cardiac Monitoring: Essential for patients receiving doxorubicin, given the risk of cardiotoxicity.
Pitfalls:
- Over-palpation: Excessive or vigorous palpation of the abdominal mass can lead to tumor rupture and upstage the disease, worsening prognosis.
- Unnecessary Biopsy: Performing an open biopsy for a classic Wilms tumor on imaging (COG approach) risks tumor spill and upstaging.
- Delay in Referral: Prompt referral to a pediatric oncology center is crucial.
- Missing Bilateral Disease: Always ensure the contralateral kidney is thoroughly evaluated on imaging, as synchronous bilateral tumors occur in 5-10% of cases.

Recent Updates

Guidelines: Current treatment guidelines are primarily driven by ongoing clinical trials from the Children's Oncology Group (COG) in North America and the International Society of Pediatric Oncology (SIOP) in Europe. These consortia regularly update their protocols based on new evidence.
Evidence:
- Risk Stratification: Refined risk stratification based on molecular markers (e.g., LOH at 1p, 16q; gain of 1q) and detailed anaplasia assessment is leading to more tailored therapy, especially for patients with anaplastic histology or those at high risk of relapse.
- Reduced Therapy Trials: Ongoing trials are exploring the possibility of reducing therapy (e.g., fewer cycles, lower doses) for very low-risk or excellent-response groups to minimize long-term toxicities, while maintaining excellent survival rates.
- Targeted Therapies: Research into targeted agents (e.g., inhibitors of IGF1R, Wnt/beta-catenin pathway, or new immune therapies) is in early phases for refractory or high-risk Wilms tumor.
Controversies:
- Upfront Surgery vs. Pre-operative Chemotherapy: The COG vs. SIOP debate remains, with each approach demonstrating excellent outcomes. The choice largely depends on geographic practice patterns and institutional expertise.
- Role of Routine Biopsy: Whether pre-operative biopsy should be routinely performed (SIOP approach) or avoided (COG approach) continues to be debated in specific scenarios, especially atypical presentations.
- Management of Renal Vein/IVC Thrombus: Ongoing refinement of surgical techniques and the role of neoadjuvant therapy for these complex cases.

Key References

Guidelines:
- Children's Oncology Group (COG) Wilms Tumor Protocols (AREN series): E.g., AREN0532, AREN03B2. These are the most current and comprehensive guidelines for North American practice. Accessible via clinical trial consortia.
- International Society of Pediatric Oncology (SIOP) Wilms Tumor Studies (e.g., SIOP-WT-2001, SIOP-RTSG): Key guidelines for European practice.
Studies:
- Landmark COG and SIOP publications: Published in journals like Journal of Clinical Oncology, Lancet Oncology, Cancer, New England Journal of Medicine, detailing the results of large, multi-institutional clinical trials that have defined current treatment paradigms.
Reviews:
- Pediatric Clinical Oncology Textbooks: E.g., Pizzo and Poplack's Pediatric Oncology, Nathan and Oski's Hematology and Oncology of Childhood.
- Comprehensive Review Articles: Found in leading medical journals, summarizing the current state of knowledge and recent advances in Wilms tumor.